Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Francesco Massari,Matteo Santoni,Hideki Takeshita,Yohei Okada, Jose Carlos Tapia,Umberto Basso,Marco Maruzzo,Sarah Scagliarini,Thomas Büttner,Giuseppe Fornarini,Zin W. Myint,Luca Galli,Vinicius Carrera Souza,Renate Pichler,Ugo De Giorgi, Nathalia Gandur,Elaine T. Lam,Danielle Gilbert,Lazar Popovic,Enrique Grande,Giulia Mammone,Rossana Berardi,Simon J. Crabb, Robert Kemp,Javier Molina-Cerrillo, Marcelo Freitas,Murilo Luz,Roberto Iacovelli,Fabio Calabrò,Deniz Tural,Francesco Atzori,Zsófia Küronya,Rita Chiari, Saul Campos,Orazio Caffo,André P. Fay,Jakub Kucharz,Paolo Andrea Zucali,José Augusto Rinck,Annalisa Zeppellini,Diogo Assed Bastos,Gaetano Aurilio, Augusto Mota, Karine Trindade, Cinzia Ortega, Juan Pablo Sade,Mimma Rizzo,Ondřej Fiala,Nuno Vau,Patrizia Giannatempo, Allan Barillas,Fernando Sabino M. Monteiro, Breno Dauster,Alessia Mennitto,Lucas Nogueira,Roni de Carvalho Fernandes,Emmanuel Seront, Luís Garcia Aceituno,Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernandez,Maria Bassanelli, Ray Manneh Kopp,Giandomenico Roviello,Halima Abahssain,Giuseppe Procopio,Michele Milella,Jindrich Kopecky,Angelo Martignetti,Carlo Messina,Manuel Caitano, Eva Inman,Ravindran Kanesvaran, Daniel Herchhorn,Daniele Santini,Aristotelis Bamias,Renato Bisonni,Alessandra Mosca,Franco Morelli,Fernando Maluf,Andrey Soares, Fernando Nunes,Alvaro Pinto,Anca Zgura,Lorena Incorvaia,Jawaher Ansari,Ignacio Ortego Zabalza, Johannes Landmesser,Alessandro Rizzo,Veronica Mollica,Andrea Marchetti,Matteo Rosellini,Giulia Sorgentoni,Nicola Battelli,Sebastiano Buti,Camillo Porta,Joaquim Bellmunt

Cancer Immunology, Immunotherapy（2024）

引用 0|浏览10

暂无评分

摘要

Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). Cox proportional hazards models were adopted to explore the presence of prognostic factors. In total, 836 patients were included: 544 patients (65

查看译文

关键词

ARON-2 study,Pembrolizumab,Real-world data,Survival,Tumor response,Urothelial cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要